Literature DB >> 2502043

A purification method for apolipoprotein A-I and A-II.

M C Peitsch1, A Kress, P G Lerch, J J Morgenthaler, H Isliker, H J Heiniger.   

Abstract

Apolipoproteins A-I and A-II were isolated from precipitates obtained by cold ethanol fractionation of human plasma. The starting material used in this report was precipitate B of the Kistler and Nitschmann method which corresponds approximately to fraction III of the Cohn and Oncley procedure. Through the use of urea, chloroform, and ethanol in appropriate concentrations, apolipoproteins A-I and A-II were isolated by a simple extraction technique avoiding time-consuming ultracentrifugation. Starting from 10 g of centrifuged precipitate B, approximately 100 mg of apolipoprotein A-I and 10 mg of apolipoprotein A-II were obtained. When incubated with normal human or rabbit plasma, both apolipoproteins were readily incorporated into high-density lipoproteins. Apolipoprotein A-I obtained by the cold ethanol method activated lecithin-cholesterol acyltransferase to the same extent as apolipoprotein A-I prepared by the classical flotation method. Apolipoprotein A-II had no such properties by itself, but was capable of potentiating lecithin-cholesterol acyltransferase activity of apolipoprotein A-I.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2502043     DOI: 10.1016/0003-2697(89)90642-8

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  3 in total

1.  Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I.

Authors:  W A Flegel; M W Baumstark; C Weinstock; A Berg; H Northoff
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

Review 2.  Modern plasma fractionation.

Authors:  Thierry Burnouf
Journal:  Transfus Med Rev       Date:  2007-04

3.  Sterically stabilized recombined HDL composed of modified apolipoprotein A-I for efficient targeting toward glioma cells.

Authors:  Jin Li; Mengmeng Han; Jianfei Li; Zhiming Ge; Qianqian Wang; Kai Zhou; Xiaoxing Yin
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.